How has been the historical performance of Zenith Drugs?

Answer:The historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability.

Breakdown:
Zenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, from 68.58 Cr in March 2022 to 134.97 Cr in March 2024, reflecting a robust expansion strategy. Cash flow from operating activities has been negative in recent years, but cash flow from investing activities turned positive in March 2024, contributing to a net cash inflow of 8.00 Cr. Overall, Zenith Drugs has demonstrated strong growth in sales and profitability, alongside an expanding asset base, despite challenges in cash flow from operations.